Insider buying · SEC Form 4

IAM insider buying

Open-market purchases of Iambic Therapeutics, Inc. (IAM) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.

1insider buy on record
$11.5Mbought in total
1insider
0by CEOs, CFOs and other chiefs
Oct 20, 2026latest scan with a buy

Every recorded buy

ScanInsiderValueSharesAvg priceTypeFiled
Oct 20, 2026Evan Lockwood RachlinDirector$11.5M718,750$16.00AddedOct 19, 2026
Form 4 ↗
718,750 shares at $16.00 (IPO price), Oct 16 trade date, via Ascenta Capital Fund I. Now $16.34 (+2.1% since buy). Purchased on IPO day alongside preferred-to-common conversions. Strong insider conviction at deal price.

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.